International Journal of Innovations & Research Analysis (IJIRA)
ISSN :2583-0295, Impact Factor: 7.662, Volume 05, No. 02(II), April- June, 2025, pp 18-28

A Review of Multiplex PCR-Based Diagnosis of Lower Respiratory Tract Infections Using the BioFire® FilmArray® Pneumonia Panel in Western Rajasthan

Ruchika Kaushik[1*] | Prabhu Prakash[2] | Sanju Pannu[3] | Richa Agrawal[4]

[1]PG Student (Biotechnology), Department of Life Sciences, Lachoo Memorial College of Science and Technology (Autonomous), Jodhpur, Rajasthan, India.
[2]Senior Professor and Head, Department of Microbiology, Dr. S.N. Medical College, Jodhpur, Rajasthan, India.
[3]Assistant Professor, Department of Microbiology, Dr. S.N. Medical College, Jodhpur, Rajasthan, India.
[4]Assistant Professor, Department of Microbiology, Dr. S.N. Medical College, Jodhpur, Rajasthan, India.

*Corresponding Author: ruchikakaushik42@gmail.com

DOI: 10.62823/IJIRA/5.2(II).7637

ABSTRACT

Lower respiratory tract infections (LRTIs) pose a major health challenge in developing regions like India due to high morbidity and mortality. Traditional diagnostic methods are often slow, insensitive, and limited in scope, contributing to treatment delays and rising antimicrobial resistance (AMR). This study, conducted at a tertiary care hospital in Western Rajasthan, evaluated the BioFire® FilmArray® Pneumonia Panel, a rapid multiplex PCR tool that detects a wide range of pathogens and AMR genes in under an hour. Over a four-month period (Feb–May 2025), 30 respiratory samples—including sputum, endotracheal aspirates, and bronchoalveolar lavage—were tested. Pathogens were detected in 80% of cases. Common bacteria included Staphylococcus aureus, Haemophilus influenzae, and Acinetobacter baumannii complex; viruses such as Influenza B and Coronavirus were also found. Resistance genes like bla_{NDM}, bla_{CTX-M}, and mecA/C indicated multidrug resistance. The BioFire® Panel offers a rapid, accurate alternative to conventional diagnostics, with significant potential for improving LRTI management in resource-limited settings.

Keywords: *Respiratory Tract Infections, Multiplex PCR, Clinical Impact, Molecular Diagnostics, and Rapid Diagnostics.*

Introduction

Lower respiratory tract infections (LRTIs) remain a leading cause of morbidity and mortality worldwide, particularly among children, the elderly, and immunocompromised individuals [1]. Despite healthcare advances, timely and accurate pathogen detection remains a major challenge [2]. Pneumonia, a common LRTI, accounts for millions of hospitalizations and significant deaths, especially in low-resource settings.

Traditional diagnostic methods—such as sputum culture, Gram staining, and antigen detection—often lack sensitivity, are time-consuming, and fail to identify viral or atypical pathogens [3,4]. This leads to the frequent empirical use of broad-spectrum antibiotics, fueling the global rise in antimicrobial resistance (AMR) [5,6].

Recent advances in molecular diagnostics, especially multiplex PCR platforms, provide faster and more comprehensive detection of respiratory pathogens [7]. The BioFire® FilmArray® Pneumonia Panel stands out by identifying bacteria, viruses, and AMR genes directly from clinical samples within an hour [8]. This enables early, targeted treatment and supports improved antimicrobial stewardship.

This review evaluates the utility of the BioFire® FilmArray® Pneumonia Panel in identifying LRTI pathogens at a tertiary care hospital in Western Rajasthan. It assesses diagnostic yield, common pathogens, resistance patterns, and the panel's impact on clinical decision-making in respiratory infection management.

Technical Overview of the Biofire® Filmarray® Pneumonia Panel

The BioFire® FilmArray® Pneumonia Panel is a fully automated multiplex PCR system that detects multiple respiratory pathogens and key AMR genes from lower respiratory samples in a single run. It delivers results in about an hour, enabling timely and accurate management of LRTIs [7].

Principle and Workflow

The BioFire system utilizes a single-use, self-contained pouch containing all necessary reagents for nucleic acid extraction, amplification, and detection. After mixing the respiratory sample (e.g., sputum, BAL, or endotracheal aspirate) with a buffer and loading it into the pouch, the system automatically performs all processing steps:

- **Mechanical lysis** of the specimen via bead beating
- **Nucleic acid extraction and purification** using magnetic bead technology
- **Reverse transcription** (for RNA viruses) and **nested multiplex PCR** amplification
- **Melting curve analysis** for target detection
- **Semi-quantitative estimation** of bacterial load using real-time amplification data compared to quantified standards (QSM).

Pathogen and Resistance Detection

The panel identifies **33 respiratory pathogens** [8], comprising:

- **18 bacterial targets**, including *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter spp.*, and atypical pathogens like *Mycoplasma pneumoniae*
- **8 viral targets**, such as Influenza A/B, RSV, adenovirus, and coronaviruses (including SARS-CoV-2)
- **7 AMR genes**, including those associated with ESBLs (*blaCTX-M*), carbapenemases (*blaNDM*, *blaKPC*, *blaOXA-48-like*), and methicillin resistance (*mecA/C*, *MREJ*)

Specimen Types and Handling

The system is validated for BAL-like (bronchoalveolar lavage, mini-BAL) and sputum-like (sputum, endotracheal aspirates) samples. A minimum of 200 µL is required. Samples should be tested promptly or stored at 2–8°C for up to 24 hours. Specimens must not be centrifuged or treated with mucolytic agents before testing.

Operational Efficiency

BioFire offers three instrument versions—FilmArray 1.5, 2.0, and Torch—all supporting standardized protocols with minimal operator input. The user-friendly software includes barcode scanning and real-time progress tracking. Each test delivers results in under 70 minutes, making the system ideal for critical-care and emergency settings.

Advantages Over Conventional Methods

- **Rapid multiplex detection** compared to slow and often inconclusive cultures
- **Identification of co-infections** and pathogens not detected by traditional methods
- **Simultaneous AMR gene detection**, aiding in early antimicrobial stewardship
- **Semi-quantitative bacterial load reporting**, helping differentiate colonization from active infection

The BioFire® FilmArray® Pneumonia Panel thus represents a significant advancement in molecular diagnostics for respiratory infections, particularly in settings with high disease burden and antibiotic resistance like tertiary care hospitals in India.

Diagnostic Performance of the Biofire® Filmarray® Pneumonia Panel

The BioFire® FilmArray® Pneumonia Panel has shown high diagnostic accuracy for LRTIs, outperforming conventional methods [9]. In this study from a tertiary care center in Western Rajasthan, pathogens were detected in 24 of 30 samples, yielding an 80% diagnostic rate. This underscores the panel's strong sensitivity and effectiveness in clarifying LRTIetiology.

The panel rapidly detects 33 respiratory pathogens—including 18 bacteria, 8 viruses, and 7 AMR genes—within about an hour, supporting early, targeted treatment and reducing empirical antibiotic use. A major strength is its ability to identify co-infections; in this study, several samples revealed multiple

pathogens. Additionally, semi-quantitative bacterial load reporting helped differentiate colonization from active infection, especially with common commensals.

The BioFire panel detected key AMR genes, including carbapenemases (NDM, KPC, VIM, OXA-48-like), ESBLs (CTX-M), and mecA/C with MREJ for MRSA. This rapid genotypic profiling enables timely, targeted therapy and supports antimicrobial stewardship. Unlike traditional methods that take 48–72 hours and may yield inconclusive results—especially in patients already on antibiotics—the BioFire system offers faster, more reliable insights.

Clinical Impact

By providing **rapid, comprehensive, and accurate identification of pathogens and key antimicrobial resistance (AMR) genes**, this multiplex PCR-based tool enhances both diagnostic precision and clinical decision-making [10, 11, 12].

A key clinical advantage of the BioFire panel is its rapid turnaround—providing results in under 70 minutes compared to 48–72 hours for traditional cultures. This allows for earlier, targeted therapy, which is crucial in critical care and emergency settings. Its ability to detect bacterial, viral, and atypical pathogens simultaneously also aids in avoiding unnecessary antibiotic use, supporting antimicrobial stewardship—a critical need amid rising global antibiotic resistance [13].

The semi-quantitative bacterial load data helps distinguish colonization from active infection, particularly in complex pulmonary cases and polymicrobial samples like sputum. Additionally, rapid detection of AMR genes (e.g., blaNDM, blaKPC, mecA/C, CTX-M) directly from samples enables timely selection of effective antibiotics, reducing treatment failure, limiting broad-spectrum use, and potentially shortening hospital stays.

In the present study conducted in Western Rajasthan, the use of the BioFire panel led to the identification of pathogens in 80% of cases, many of which were not detectable by conventional culture. Such high diagnostic yield underscores its role in **improving patient outcomes**, especially in settings with high prevalence of resistant infections.

Comparison of the Biofire® Filmarray® Pneumonia Panel with other Syndromic Diagnostic Panels

Syndromic diagnostic panels have transformed infectious disease diagnostics by enabling rapid, simultaneous detection of multiple pathogens from a single sample. The BioFire® FilmArray® Pneumonia Panel stands out for its broad coverage of respiratory pathogens and resistance markers. However, other platforms exist, and comparisons highlight key differences in scope, turnaround time, clinical utility, and diagnostic performance.

- **Panel Composition and Pathogen Coverage**

The BioFire Pneumonia Panel detects 33 targets—18 bacteria, 8 viruses, and 7 AMR genes—making it well-suited for diagnosing LRTIs from sputum, bronchoalveolar lavage (BAL), and endotracheal aspirates [14].

In contrast:

  - **BioFire Respiratory Panel (RP2.1)** is designed primarily for **upper respiratory infections** and includes **22 viruses** and **3 bacteria**, but **lacks resistance gene detection**.
  - **GenMark ePlex® Respiratory Pathogen Panel** covers a similar range of **viral pathogens** and a few bacteria but does **not report AMR markers** or bacterial load.
  - **Luminex NxTAG® Respiratory Pathogen Panel** and **QIAstat-Dx® Respiratory Panel** also focus on **respiratory viruses**, with limited bacterial targets and **no AMR detection**.

- **Antimicrobial Resistance Detection**

The BioFire Pneumonia Panel offers a key advantage by detecting critical AMR genes such as blaKPC, blaNDM, blaOXA-48-like, and mecA/C (MRSA), aiding in informed antibiotic selection. In contrast, most other syndromic panels—like RP2.1 and NxTAG—do not detect resistance genes, limiting their contribution to antimicrobial stewardship.

- **Sample Type and Quantification**

The Pneumonia Panel is validated for sputum-like and BAL-like samples and provides semi-quantitative results (e.g., genomic copies/mL), helping differentiate infection from colonization. This feature is lacking in most viral panels, such as ePlex and RP2.1, which are non-quantitative and primarily designed for nasopharyngeal swabs—less suitable for diagnosing LRTIs.

- **Turnaround Time**

Most syndromic panels, including the BioFire Pneumonia Panel, deliver results within **60–90 minutes**, making them ideal for **emergency and ICU settings**. While comparable in speed, the **clinical depth and breadth of results vary** greatly across platforms.

- **Clinical Impact and Utility**

BioFire Pneumonia Panel plays a significant role in **critically ill or ventilated patients** with suspected bacterial pneumonia, where the identification of co-infections and resistance markers can drastically change treatment plans. Other panels are more appropriate for **outpatient or seasonal viral surveillance** but offer limited guidance for antibiotic therapy.

Summary Table: Comparative Overview

Feature	BioFirePN**Panel**	**BioFire RP2.1**	**ePlex RP Panel**	**Luminex NxTAG**
Pathogens Detected	33 (18 bacteria, 8 viruses)	22 viruses, 3 bacteria	20+ viruses, few bacteria	20+ viruses, few bacteria
AMR Gene Detection	Yes (7 genes)	No	No	No
Sample Types	**Sputum, BAL,** ETA	Nasopharyngeal swab	Nasopharyngeal swab	Nasopharyngeal swab
Quantitative Bacterial Load	Yes	No	No	No
Turnaround Time	~60 minutes	~45 minutes	~90 minutes	~120 minutes
Best Use Scenario	ICU/LRTI, AMR surveillance	OPD/viral screening	Viral epidemics	Viral respiratory infections

Application in Special Populations

The BioFire® FilmArray® Pneumonia Panel is especially valuable in high-risk groups where rapid, accurate diagnosis is essential and conventional methods often underperform. These include pediatric patients, the elderly, immunocompromised individuals, and those in ICUs or on mechanical ventilation [15, 16].

- **Pediatric Patients**

In children—especially infants—respiratory infections are a leading cause of hospitalization. Traditional methods are often limited by small sample volumes and poor specimen quality. The BioFire panel, requiring only 200 µL and detecting a broad range of pathogens (including pediatric-relevant viruses like RSV and Influenza B), supports early diagnosis and helps reduce unnecessary antibiotic use—crucial for preventing resistance in this vulnerable group.

- **Elderly Patients**

Older adults face a higher risk of severe pneumonia due to immune senescence and comorbidities like COPD and diabetes. The FilmArray Pneumonia Panel enables rapid identification of pathogens and resistance markers, supporting timely, targeted antimicrobial therapy and helping to avoid polypharmacy and treatment delays—common issues in this population.

- **Immunocompromised Individuals**

Immunocompromised patients—such as those undergoing chemotherapy, transplant recipients, or individuals with HIV/AIDS—are highly vulnerable to both common and opportunistic respiratory pathogens. The BioFire Panel's ability to rapidly detect multiple pathogens, including bacteria, viruses, and atypical organisms, makes it an effective tool for prompt diagnosis in these patients, where mixed infections are often encountered.

- **ICU and Mechanically Ventilated Patients**

In critical care settings, patients with ventilator-associated pneumonia (VAP) or hospital-acquired pneumonia (HAP) often need immediate empirical treatment. The FilmArray Pneumonia Panel, compatible with BAL and endotracheal aspirate (ETA) samples, is well-suited for ICU use. Its semi-quantitative bacterial data and detection of key resistance genes (e.g., NDM, KPC, mecA) help tailor therapy, potentially reducing ICU stay and improving patient outcomes.

- **Patients with Atypical or Refractory Infections**

The panel's ability to detect atypical pathogens like Mycoplasma pneumoniae and viral co-infections helps identify elusive pneumonia causes often missed by culture or imaging. This is especially valuable in patients unresponsive to standard antibiotics, where recognizing a viral or atypical etiology can prevent treatment delays and inappropriate management.

Application in Covid-19 and Emerging Infections

The COVID-19 pandemic underscored the urgent need for rapid, accurate respiratory diagnostics—particularly for managing co-infections and antimicrobial resistance. The BioFire® FilmArray® Pneumonia Panel proved valuable during the pandemic and remains a promising tool for pathogen detection in future emerging infectious disease scenarios [17].

- **COVID-19 Co-Infections**

COVID-19 patients are at heightened risk for secondary bacterial or viral infections, which can complicate outcomes. Differentiating between SARS-CoV-2 pneumonia and superimposed bacterial infections is critical for appropriate management. The BioFire Panel enables simultaneous detection of SARS-CoV-2, other respiratory viruses (e.g., Influenza A/B, RSV), and bacterial pathogens in a single run, helping to minimize unnecessary antibiotic use—especially crucial during viral outbreaks when empirical therapy is common.

- **Rapid Decision-Making in Critical COVID-19 Cases**

In severe COVID-19 cases, particularly those requiring ICU care or mechanical ventilation, timely detection of co-pathogens is critical. The BioFire Panel's ability to identify resistance genes (e.g., blaNDM, mecA/C, CTX-M) offers early insight into multidrug-resistant organisms, enabling faster, targeted therapy in patients with suspected hospital-acquired or ventilator-associated pneumonia.

- **Infection Control and Isolation Protocols**

Early identification of viral and bacterial pathogens allows healthcare facilities to implement **appropriate isolation precautions**, reducing nosocomial spread. This is particularly relevant during outbreaks of emerging pathogens, where **early containment** can limit transmission.

- **Utility in Future Emerging Infections**

The panel's broad detection range makes it valuable beyond COVID-19. As novel respiratory viruses continue to emerge, rapid syndromic tools like BioFire aid in early detection of known pathogens, support surveillance efforts, and enhance differential diagnosis during public health emergencies.

Global Health Implications

The BioFire® FilmArray® Pneumonia Panel marks a major step forward in addressing respiratory infections and antimicrobial resistance. With LRTIs remaining a leading cause of morbidity and mortality—especially in low- and middle-income countries (LMICs)—the adoption of rapid, multiplex diagnostics like BioFire could significantly enhance disease surveillance, clinical management, and public health strategies globally [18].

- **Enhancing Diagnostic Equity**

In resource-limited settings, conventional diagnostics are often unavailable or yield delayed, unreliable results. The BioFire Panel offers a rapid, user-friendly solution, detecting a wide range of bacterial and viral pathogens in under 90 minutes. With automated processing and minimal hands-on time, it is well-suited for low-resource laboratories, helping to bridge the diagnostic gap in underserved regions.

- **Supporting Antimicrobial Stewardship**

Antimicrobial resistance (AMR) is a growing global health crisis, and misuse of antibiotics is a major contributing factor. By rapidly identifying causative agents and resistance genes, the panel enables clinicians to **tailor antibiotic therapy** and reduce unnecessary prescriptions. This contributes directly to

slowing the spread of resistant strains, a key priority for international health agencies like WHO and CDC.

- **Strengthening Surveillance and Outbreak Response**

The BioFire Panel's ability to detect both common and emerging pathogens supports real-time surveillance and early outbreak identification. During epidemics like COVID-19 or seasonal influenza, it enables rapid detection of co-infections and circulating strains, enhancing both patient care and public health response.

- **Reducing Mortality in High-Burden Regions**

Regions with high rates of pneumonia-related deaths, such as parts of sub-Saharan Africa and South Asia, could greatly benefit from this technology. Early and accurate diagnosis leads to **prompt treatment**, reduced hospital stays, and ultimately, **lower mortality rates**, especially in children, the elderly, and immunocompromised populations.

- **Catalyzing Policy and Investment in Diagnostics**

The effectiveness of the BioFire platform highlights the importance of investing in **molecular diagnostics** for infectious diseases. Global health initiatives may increasingly prioritize such tools in their funding strategies, aligning laboratory capacity building with the broader goals of **universal health coverage** and **global health security**.

Implementation, Workflow, and Training

Successful implementation of the BioFire® FilmArray® Pneumonia Panel in clinical laboratories requires strategic planning to ensure its effectiveness, reliability, and alignment with goals like timely diagnosis and antimicrobial stewardship. Key components include infrastructure setup, workflow integration, and staff training [8].

- **Implementation and Setup**

To implement the BioFire Pneumonia Panel, laboratories need compatible instruments like the FilmArray 2.0 or Torch system. These compact devices require minimal bench space, standard power supply, a temperature-controlled environment, and basic biosafety protocols. The closed-cartridge format reduces contamination risk and simplifies safety requirements, making it suitable for both large and mid-sized facilities.

- **Workflow Integration**

The BioFire panel simplifies the diagnostic workflow. After collecting a respiratory sample (e.g., sputum, BAL, or endotracheal aspirate), it is mixed with a buffer and loaded into a self-contained pouch. The entire process takes about one hour, with only 2–5 minutes of hands-on time, allowing for efficient and rapid testing.

BioFire's integrated software guides the operator through each step and automatically generates a comprehensive report, which includes:

- Pathogens detected (bacterial/viral)
- Resistance gene profiles
- Semi-quantitative bacterial load (copies/mL for selected targets)

This report can be directly reviewed by clinicians, enabling **rapid treatment decisions** without requiring interpretive microbiology expertise.

- **Staff Training and Quality Control**

Operating the BioFire system requires **basic laboratory training**, but not advanced molecular skills. Laboratory staff can be trained within a few hours to:

- Prepare and load samples into the panel
- Operate the instrument via user-friendly software
- Interpret and relay results accurately

Manufacturers and authorized distributors often provide **on-site demonstrations, user manuals, and technical support**. Additionally, regular **quality control procedures** (e.g., running control materials, pouch integrity checks) are essential to maintain accuracy and reliability.

- **Scalability and Multi-Department Use**

The modular design of BioFire Torch supports scalability for high-throughput labs. Hospitals can integrate results directly into EMRs, enabling seamless communication across departments like ICU, emergency, and pulmonology.

Bioinformatics, Interpretation, and Data Management

The BioFire® FilmArray® Pneumonia Panel combines advanced bioinformatics with automated analysis, delivering fast, accurate results with minimal user input. This streamlines molecular diagnostics while ensuring clinical reliability and traceability.

- **Bioinformatics and Automated Analysis**

The FilmArray system uses **proprietary software** to carry out automatic result interpretation based on real-time PCR and melting curve analysis. Each test pouch includes internal controls and quantified standard material (QSM) that allow the system to:

- Confirm the validity of nucleic acid extraction and amplification
- Detect amplification of target sequences
- Estimate bacterial load in genomic copies/mL

The assay uses nested multiplex PCR to detect up to 33 targets in one run. Its software compares results to set thresholds to differentiate true pathogens from contaminants or commensals.

- **Result Interpretation and Clinical Reporting Results are automatically categorized as:**
  - **"Detected"**: Pathogen or resistance gene is present
  - **"Not Detected"**: No amplification of target sequence
  - **"Invalid"**: Test run failed (often due to inadequate sample quality or internal control failure)

For bacterial targets, the system provides semi-quantitative results (10^4 to $\geq 10^7$ copies/mL), helping differentiate colonization from true infection—especially in mixed-flora samples like sputum or endotracheal aspirates

The final output is generated as a **PDF report**, which includes the following:

- Pathogens detected and their estimated load
- Resistance genes identified
- Quality control outcomes
- Time stamp, sample ID, and operator details

- **Data Storage and Management**

All test data is stored in the **FilmArray database**, which can be backed up or exported in compliance with laboratory information system (LIS) standards. The software allows for:

- Secure storage of past results
- Audit trails for quality assurance
- Integration with hospital **electronic medical records (EMRs)** for real-time clinical access

Administrators can also review test usage, sample throughput, and instrument status, aiding in laboratory workflow optimization and **resource planning**.

- **Data Security and Compliance**

BioFire systems include user logins, password protection, and audit logs to ensure data security and regulatory compliance (e.g., HIPAA, GDPR).

Limitations and Criticisms

While the BioFire® FilmArray® Pneumonia Panel enables rapid, broad pathogen and AMR detection, it has limitations that must be considered to ensure proper clinical use and result interpretation.

- **High Cost and Limited Accessibility**

A major limitation is the high cost per test, including cartridges and equipment, which restricts routine use—especially in resource-limited settings—often reserving it for critically ill or high-priority patients.

- **Inability to Perform Phenotypic Antibiotic Sensitivity Testing**

While the panel identifies key resistance genes (e.g., mecA, blaNDM, CTX-M), it does not provide phenotypic susceptibility data. Some resistance mechanisms may be missed, and gene detection doesn't always indicate expression, so conventional culture and AST remain essential for guiding definitive therapy.

- **Detection of Colonization vs. True Infection**

The **high sensitivity** of the panel, while advantageous, may also lead to **overdiagnosis**. Especially in cases like sputum or endotracheal aspirates, the test may detect colonizing organisms or commensals. Although semi-quantitative bacterial load is provided, distinguishing **infection from colonization** can still be challenging, potentially leading to unnecessary antibiotic use.

- **Limited Range of Resistance Markers**

The panel includes a focused set of AMR genes, but **does not detect all resistance mechanisms**, such as efflux pumps, porin mutations, or certain emerging resistance genes. This could lead to an **underestimation of resistance patterns**, particularly in regions with diverse microbial resistance profiles.

- **Lack of Flexibility**

The BioFire system is closed and cannot be customized. New or emerging pathogens not included in the panel require additional testing.

- **No Detection of Fungal Pathogens**

Although fungi like Aspergillus and Pneumocystis jirovecii are key respiratory pathogens, the BioFire Pneumonia Panel does not detect them, limiting its use in immunocompromised patients.

Ethical, Legal, and Regulatory Considerations

Using molecular diagnostics like the BioFire® FilmArray® Pneumonia Panel involves important ethical, legal, and regulatory responsibilities to ensure patient safety, data privacy, proper clinical use, and compliance with laws and standards.

- **Ethical Considerations**
  - **Informed Consent**

While routine tests may not need written consent, molecular diagnostics detecting resistance genes or co-infections raise concerns about treatment and care. When results impact isolation, treatment escalation, or public health actions, clear communication with patients or families is crucial.

  - **Equity and Access**

The high cost of the BioFire panel can limit access to wealthy or urban hospitals, raising ethical concerns about healthcare inequality—especially in low-resource areas with a high pneumonia burden.

  - **Diagnostic Stewardship**

There is an ethical duty to avoid misuse or overuse of rapid diagnostics. Testing should be limited to appropriate clinical situations, not driven by availability or pressure for quick results.

- **Legal Considerations**
  - **Patient Privacy and Data Security:**

Test results contain sensitive genetic and clinical data. Facilities must follow data protection laws (e.g., HIPAA, GDPR) to secure patient information and prevent unauthorized sharing.

  - **Liability in Misinterpretation:**

While BioFire automates analysis, clinicians must interpret results carefully. Misinterpretation—like mistaking colonization for infection—can cause treatment errors and legal liabilities for providers.

- **Regulatory Oversight**
  - **Diagnostic Approval and Quality Standards:**

The BioFire Pneumonia Panel is FDA-approved and CE-IVD marked. In India and other countries, clinical use requires approval from local regulators like CDSCO.

- **Laboratory Accreditation:**

Laboratories must comply with quality standards like NABL (India), CAP (USA), or ISO 15189 to ensure proper calibration, trained personnel, and adherence to SOPs. Manufacturers must also conduct post-market surveillance and report adverse events to maintain safety and effectiveness.

Future Perspectives

The BioFire® FilmArray® Pneumonia Panel is a powerful diagnostic tool with untapped potential. As diagnostic technologies advance, the platform holds promise for expanded clinical and public health applications.

- **Expansion of Pathogen and Resistance Gene Targets**

Emerging pathogens and evolving resistance mechanisms are ongoing challenges. Future versions of the panel could include:

- **Fungal pathogens** like *Aspergillus* and *Pneumocystis jirovecii*
- **Additional resistance markers** for more comprehensive coverage, such as efflux pump genes or plasmid-mediated colistin resistance
- **Strain-specific information** (e.g., MRSA clonal types, influenza subtypes) to assist in epidemiological tracking

- **Integration with Real-Time Surveillance Systems**

The FilmArray platform could significantly enhance public health surveillance by integrating with regional or national databases. Real-time data sharing on pathogen prevalence and resistance patterns would support faster outbreak detection and more coordinated public health responses.

- **Cost Reduction and Wider Accessibility**

Technological progress and broader adoption are expected to reduce testing costs, enhancing accessibility in low-resource settings. Partnerships with governments and global health agencies could support subsidized implementation in high-burden areas, promoting greater diagnostic equity.

- **Personalized Medicine and Predictive Analytics**

As molecular diagnostics integrate with **electronic medical records (EMRs)** and **artificial intelligence (AI)** platforms, future systems may offer:

- Predictive models for disease severity
- Guidance on optimized, patient-specific treatment plans
- Alerts for early signs of treatment failure or resistance

- **Point-of-Care Adaptation**

Miniaturizing and automating the technology could enable point-of-care versions for use in emergency rooms, ICUs, and field hospitals. This would deliver rapid, lab-quality diagnostics at the bedside—crucial during pandemics or in disaster-response scenarios.

Research Gaps and Opportunities

Despite the strong diagnostic capabilities of the BioFire® FilmArray® Pneumonia Panel, key research gaps persist. Exploring these areas could improve clinical utility, optimize test deployment, and support its integration into comprehensive healthcare and antimicrobial stewardship programs.

- **Limited Large-Scale, Multicenter Outcome Studies**

While multiple smaller studies have demonstrated high diagnostic yield and reduced time to treatment, **large-scale, multicenter trials** evaluating its impact on patient outcomes, antibiotic stewardship, and healthcare costs are limited. Further research is needed to **quantify benefits** in diverse healthcare settings, particularly in resource limited regions.

- **Colonization vs. True Infection Discrimination**

The BioFire® Pneumonia Panel provides semi-quantitative data, but distinguishing infection from colonization remains challenging. Combining it with biomarkers like procalcitonin or CRP could improve accuracy, warranting further research.

- **Diagnostic Role in Specific Subpopulations**

More research is needed on the panel's use in special populations like immunocompromised patients, neonates, and those with chronic lung disease to improve test application and personalized care.

- **Economic and Cost-Effectiveness Analyses**

Despite its speed and accuracy, the test's high cost restricts broad use. Cost-effectiveness studies in low- and middle-income countries are needed to support policy and investment decisions.

- **Integration with Therapeutic Algorithms**

Current guidelines offer limited direction on managing multiplex PCR results with multiple pathogens or resistance genes. Developing standardized treatment protocols that incorporate BioFire findings can improve clinical decision-making.

- **Research on Emerging and Neglected Pathogens**

The panel lacks coverage for fungi and some region-specific pathogens. Research on local pathogen trends, especially in tropical and rural areas, is needed to guide future panel updates.

Conclusion

The BioFire® FilmArray® Pneumonia Panel represents a major step forward in diagnosing lower respiratory tract infections (LRTIs). In this study at a tertiary care center in Western Rajasthan, it showed an 80% detection rate for respiratory pathogens. By identifying both pathogens and key AMR genes, the panel enables early, targeted treatment and improves patient care.

The multiplex PCR platform offers key advantages over conventional methods, including rapid results, broad pathogen detection, and semi-quantitative bacterial load data to support clinical decisions. Its ability to identify resistance genes like NDM, KPC, and CTX-M strengthens antibiotic stewardship and helps combat drug-resistant infections.

This study highlights the value of integrating molecular diagnostics into routine care, especially in high-burden areas where traditional methods fall short. Despite challenges like cost and limited resistance detection, the BioFire panel offers improved diagnostic accuracy and supports more targeted, evidence-based treatment decisions.

Looking ahead, wider adoption of this technology—along with more research on its cost-effectiveness, use in varied populations, and alignment with treatment protocols—could greatly enhance LRTI diagnostics and support global efforts to combat antimicrobial resistance.

Acknowledgement

I would like to express my sincere gratitude to Department of Microbiology, Dr. S.N. Medical College, Jodhpur, for providing the laboratory facilities and technical support required for this research.

References

1. World Health Organization. Global health estimates 2022: Deaths by cause, age, sex, by country and by region, 2000–2019. Geneva: World Health Organization; 2022.
2. GBD 2019 India Collaborators. Mortality, morbidity, and risk factors in India and its states, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2021;397(10286):2467–76. https://doi.org/10.1016/S0140-6736(21)00580-7
3. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med. 1995;333(24):1618–24. https://doi.org/10.1056/NEJM199512143332407
4. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl_2):S27–72. https://doi.org/10.1086/511159
5. Tucker E, O'Sullivan M, Waddell L. Controversies in the management of community-acquired pneumonia in adults. AustPrescr. 2024;47(3):80–4. https://doi.org/10.18773/austprescr.2024.024
6. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309–18. https://doi.org/10.1179/2047773215Y.0000000030

7. Ramanan L, Zong K, Gross T, et al. Antibiotic resistance: Research priorities and product development needs. Indian J Med Res. 2020;152(2):112–20.
8. BioFire Diagnostics, LLC. BioFire® FilmArray® Pneumonia Panel Instruction Booklet (RFIT-PRT-0575). Salt Lake City, UT: BioFire Diagnostics; 2022.
9. Szymankiewicz MT, Szczepanska A, Stefaniuk E. Evaluation of the BioFire® FilmArray® Pneumonia plus Panel for detecting bacterial etiological agents of lower respiratory tract infections in an oncologic hospital: Comparison with conventional culture method. Pol J Microbiol. 2023;72(4):391–8.
10. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309–18.
11. Bhargava A, Khurana S, Bhardwaj R, et al. A study of etiology and antimicrobial resistance patterns in lower respiratory tract infections using multiplex PCR. Indian J Med Microbiol. 2020;38(4):533–8.
12. Indian Council of Medical Research. Annual report 2022: Antimicrobial resistance research & surveillance. New Delhi: ICMR; 2022.
13. Markussen DL, Serigstad S, Ritz C, Knoop ST, Ebbesen MH, Faurholt-Jepsen D, et al. Diagnostic stewardship in community-acquired pneumonia with syndromic molecular testing: A randomized clinical trial. JAMA Netw Open. 2024;7(3):e240830. https://doi.org/10.1001/jamanetworkopen.2024.0830
14. West DM, West MA, Burnham CA, Anderson NW. Evaluation of the BioFireFilmArray Pneumonia Panel for detection of viral and bacterial pathogens in lower respiratory tract specimens in the setting of a tertiary care academic medical center. J Clin Microbiol. 2020;58(7):e00343-20. https://doi.org/10.1128/JCM.00343-20
15. Falsey AR, Branche AR, Croft DP, Formica MA, Peasley MR, Walsh EE. Real-life assessment of BioFireFilmArray Pneumonia Panel in adults hospitalized with respiratory illness. J Infect Dis. 2024;229(1):214–22.
16. Kamel NA, Alshahrani MY, Aboshanab KM, El Borhamy MI. Evaluation of the BioFireFilmArray Pneumonia Panel Plus compared to the conventional diagnostic methods in determining the microbiological etiology of hospital-acquired pneumonia. Biology (Basel). 2022;11(3):377. https://doi.org/10.3390/biology11030377
17. Mishra M, Shendre P, Gade N, Shete V, Nag S, Dutta SMV. Impact of BioFireFilmArray multiplex PCR in the detection of microbial agents causing severe acute respiratory infection in the COVID-19 era: A cross-sectional study from a tertiary care hospital in Central India. J Clin Diagn Res. 2024;18(1):DC06–12. https://doi.org/10.7860/JCDR/2024/65688.18972\
18. Leber AL, Everhart K, Balada-Llasat JM, et al. Multicenter evaluation of BioFireFilmArray Pneumonia Panel for pathogen detection in lower respiratory tract infections. J Clin Microbiol. 2018;56(9):e01945-17.
19. https://doi.org/10.1128/JCM.01945-17.

❑❍❑